Indication
Metastatic Osteosarcoma
8 clinical trials
6 products
4 drugs
Clinical trial
Phase I/II Study of Aerosol Interleukin-2 for Pulmonary MetastasesStatus: Active (not recruiting), Estimated PCD: 2026-04-30
Product
AldesleukinClinical trial
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent OsteosarcomaStatus: Completed, Estimated PCD: 2020-03-31
Drug
DinutuximabDrug
GM-CSFClinical trial
Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory OsteosarcomaStatus: Completed, Estimated PCD: 2019-12-31
Product
DenosumabClinical trial
A Phase 2 Trial of Atezolizumab and Cabozantinib in Adolescents and Young Adults With Recurrent/Metastatic Osteosarcoma (TACOS)Status: , Estimated PCD: 2027-12-31
Drug
AtezolizumabProduct
CabozantinibClinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing SarcomasStatus: Active (not recruiting), Estimated PCD: 2019-06-30
Clinical trial
A Phase II Multi-Arm Study to Test the Efficacy of Oleclumab and Durvalumab in Multiple Sarcoma SubtypesStatus: Recruiting, Estimated PCD: 2024-06-30
Drug
AN0025Product
OleclumabClinical trial
An Open Label, Single Centre, Single Arm, Prospective Feasibility Study Evaluating the Effectiveness of Near-infrared Fluorescence (NIRF) Using Indo-cyanine Green (ICG) in Minimally Invasive Paediatric Oncology Surgery (MIS)Status: Completed, Estimated PCD: 2022-09-30
Product
Indocyanine greenClinical trial
KB707-02: A Phase 1 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the LungsStatus: Recruiting, Estimated PCD: 2027-02-01
Product
KB707